Biotech company Cybin has filed an international patent application related to methods for the delivery of psychedelic medications.
Cybin Inc. has filed an international patent application for the delivery of psychedelic medications by inhalation, as well as devices for performing those methods.
The application, governed by the Patent Cooperation Treaty, brings the potential to obtain patent coverage in 153 countries.
Cybin CEO, Doug Drysdale, commented: “The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches.
“Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions.”
Cybin says it believes the delivery of psychedelic medications using inhalation may overcome key obstacles encountered by traditional oral drug administration., specifically, inhalation delivery to facilitate optimised psychedelic session timing compared to oral administration, lower doses of psychedelic therapeutics while preserving efficacy, and providing health care providers with more control during psychedelic sessions.
The filing also includes support for future research programmes respecting various systems which seek to minimise certain side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions.
